ITEMS IN AFP WITH KEYWORD:
May 1, 2013 Issue
Dietary Fat Modification and the Risk of Future Cardiovascular Events and Mortality [Cochrane for Clinicians]
According to the authors of this Cochrane review, reducing or modifying a patient's dietary fat intake did not lower the rates of either total or cardiovascular-related mortality when compared with usual or control diets. Reducing the intake of total or saturated fats decreased the risk of cardiovas...
Dec 15, 2012 Issue
Cardiovascular Risk of Combined Oral Contraceptive Use [FPIN's Clinical Inquiries]
Because of an increased risk of cardiovascular disease, the use of combined oral contraceptives (OCs) should be considered carefully in women who smoke and in those with hypertension or hyperlipidemia.
Dec 1, 2012 Issue
AHA Releases Statement on Sexual Activity and Cardiovascular Disease [Practice Guidelines]
Decreased sexual activity and sexual dysfunction are common in patients with cardiovascular disease (CVD), and can lead to anxiety and depression. The American Heart Association (AHA) has published a scientific statement synthesizing data relevant to sexual activity and heart disease to provide reco...
Evidence indicates that reducing risk can slow the progression of cardiovascular disease (CVD); therefore, the National Heart, Lung, and Blood Institute (NHBLI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents developed guidelines to help...
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects approximately one out of every 500 persons. The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have updated guidelines on the diagnosis and treatment of HCM.
Jul 1, 2012 Issue
Adding ACE Inhibitors or ARBs to Standard Therapy for Stable Ischemic Heart Disease [Implementing AHRQ Effective Health Care Reviews]
Are there clinical advantages to augmenting standard therapy for stable ischemic heart disease with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)?
Major changes addressed in the American Heart Association's (AHA) 2011 guidelines on cardiovascular disease (CVD) are that benefits and risks found in the clinical practice setting were strongly considered, and recommendations were not based solely on benefits found in the clinical research setting....
Jul 15, 2011 Issue
ACCF/AHA Release Guideline for Early Cardiovascular Risk Assessment [Practice Guidelines]
Atherosclerotic cardiovascular disease is the leading cause of death among adults in the United States. Because coronary heart disease (CHD) has a long asymptomatic latent period, there is an opportunity for early preventive measures. The American College of Cardiology Foundation (ACCF) and the Amer...
Jun 15, 2011 Issue
Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends the use of aspirin in men 45 to 79 years of age when the potential benefit of a reduction in myocardial infarctions (MIs) outweighs the potential harm of an increase in gastrointestinal (GI) hemorrhage.
Jun 15, 2011 Issue
Aspirin for the Prevention of Cardiovascular Disease [Putting Prevention into Practice]
Case study: K.T., a 48-year-old man, presents for a routine office visit. He is worried about cardiovascular disease (CVD) and asks whether he should take daily aspirin to lower his risk. His blood pressure is 120/60 mm Hg, and his total cholesterol is 180 mg per dL (4.66 mmol per L), with a low-den...